CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas

CMTM6, a previously uncharacterized protein, was identified as a critical regulator of PD-L1, which is reported as an immune checkpoint inhibitor, to modulate the T cell activities both in vitro and in vivo of other tumors. However, the role of CMTM6 has so far remained unclear in glioma. To investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiudong, Zhang, Chuanbao, Zhao, Jingyan, Sun, George, Song, Qingkun, Jia, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156716/
https://www.ncbi.nlm.nih.gov/pubmed/30131308
http://dx.doi.org/10.1016/j.ebiom.2018.08.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156716/
https://www.ncbi.nlm.nih.gov/pubmed/30131308
http://dx.doi.org/10.1016/j.ebiom.2018.08.012

Ejemplares similares